Cargando…

The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus

Triple-negative breast cancer (TNBC) is an aggressive and heterogeneous subgroup of breast tumors clinically defined by the lack of estrogen, progesterone and HER2 receptors, limiting the use of the targeted therapies employed in other breast malignancies. Recent evidence indicates that c-MYC is a k...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vázquez, Ramiro, Riveiro, María E, Astorgues-Xerri, Lucile, Odore, Elodie, Rezai, Keyvan, Erba, Eugenio, Panini, Nicolò, Rinaldi, Andrea, Kwee, Ivo, Beltrame, Luca, Bekradda, Mohamed, Cvitkovic, Esteban, Bertoni, Francesco, Frapolli, Roberta, D'Incalci, Maurizio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352346/ https://www.ncbi.nlm.nih.gov/pubmed/27935867 http://dx.doi.org/10.18632/oncotarget.13814

Ejemplares similares

OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations
por: Riveiro, Maria E., et al.
Publicado: (2016)

Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma
por: Gaudio, Eugenio, et al.
Publicado: (2016)

Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes
por: Boi, Michela, et al.
Publicado: (2016)

Biological Effects of BET Inhibition by OTX015 (MK-8628) and JQ1 in NPM1-Mutated (NPM1c) Acute Myeloid Leukemia (AML)
por: Djamai, Hanane, et al.
Publicado: (2021)

The synergistic anticancer effect of the bromodomain inhibitor OTX015 and histone deacetylase 6 inhibitor WT-161 in osteosarcoma
por: Yu, Bo, et al.
Publicado: (2022)

CLRM-04. PHASE I/II SAFETY AND EFFICACY STUDY OF BET BROMODOMAIN INHIBITOR OTX-015 WITH OLAPARIB AND LOMUSTINE IN PATIENTS WITH RECURRENT GLIOBLASTOMA
por: Lam, Fred
Publicado: (2021)

BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells
por: Coudé, Marie-Magdelaine, et al.
Publicado: (2015)

BET bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistance
por: Tarantelli, Chiara, et al.
Publicado: (2018)

The BET inhibitor OTX015 reactivates latent HIV-1 through P-TEFb
por: Lu, Panpan, et al.
Publicado: (2016)

Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin
por: Colmegna, B, et al.
Publicado: (2015)

New activities for the anti-tumor agent trabectedin: taking two birds with one stone
por: D'Incalci, Maurizio, et al.
Publicado: (2013)

The BET Inhibitor OTX015 Exhibits In Vitro and In Vivo Antitumor Activity in Pediatric Ependymoma Stem Cell Models
por: Servidei, Tiziana, et al.
Publicado: (2021)

Effects of the Anti-Tumor Agents Trabectedin and Lurbinectedin on Immune Cells of the Tumor Microenvironment
por: Allavena, Paola, et al.
Publicado: (2022)

Targeting Adrenomedullin in Oncology: A Feasible Strategy With Potential as Much More Than an Alternative Anti-Angiogenic Therapy
por: Vázquez, Ramiro, et al.
Publicado: (2021)

Time dependence of the in vitro cytotoxicity of hexamethylmelamine and its metabolites.
por: D'Incalci, M., et al.
Publicado: (1980)

The MDM2 inhibitor CGM097 combined with the BET inhibitor OTX015 induces cell death and inhibits tumor growth in models of neuroblastoma
por: Maser, Tyler, et al.
Publicado: (2020)

Synergism between 5-fluorouracil and N-methylformamide in HT29 human colon cancer line.
por: Laudonio, N., et al.
Publicado: (1990)

Mechanism of cytotoxicity of 5,10-dideazatetrahydrofolic acid in human ovarian carcinoma cells in vitro and modulation of the drug activity by folic or folinic acid.
por: Erba, E., et al.
Publicado: (1994)

Role of membrane folate-binding protein in the cytotoxicity of 5,10-dideazatetrahydrofolic acid in human ovarian carcinoma cell lines in vitro.
por: Sen, S., et al.
Publicado: (1996)

Mechanism of action of trabectedin in desmoplastic small round cell tumor cells
por: Uboldi, S., et al.
Publicado: (2017)

MODL-15. THE COMBINATION TREATMENT OF PARP INHIBITOR AND TMZ, OR DAG WILL BE PROMISING TREATMENT IN SF8628
por: Ohba, Shigeo, et al.
Publicado: (2020)

PEGylated recombinant human hyaluronidase (PEGPH20) pre-treatment improves intra-tumour distribution and efficacy of paclitaxel in preclinical models
por: Morosi, Lavinia, et al.
Publicado: (2021)

OTX015 Epi-Drug Exerts Antitumor Effects in Ovarian Cancer Cells by Blocking GNL3-Mediated Radioresistance Mechanisms: Cellular, Molecular and Computational Evidence
por: Megiorni, Francesca, et al.
Publicado: (2021)

Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models
por: Belgiovine, Cristina, et al.
Publicado: (2017)

Trabectedin modulates the senescence-associated secretory phenotype and promotes cell death in senescent tumor cells by targeting NF-κB
por: Camorani, Simona, et al.
Publicado: (2018)

A systems biology approach to investigate the mechanism of action of trabectedin in a model of myelomonocytic leukemia
por: Mannarino, L, et al.
Publicado: (2018)

Inhibition of tumor‐associated macrophages by trabectedin improves the antitumor adaptive immunity in response to anti‐PD‐1 therapy
por: Belgiovine, Cristina, et al.
Publicado: (2021)

OTX1 and OTX2 as Possible Molecular Markers of Sinonasal Carcinomas and Olfactory Neuroblastomas
por: Pirrone, Cristina, et al.
Publicado: (2017)

Treatment with inhibitors of polyamine biosynthesis, which selectively lower intracellular spermine, does not affect the activity of alkylating agents but antagonizes the cytotoxicity of DNA topoisomerase II inhibitors.
por: Desiderio, M. A., et al.
Publicado: (1997)

Optimization of a Luciferase-Expressing Non-Invasive Intrapleural Model of Malignant Mesothelioma in Immunocompetent Mice
por: Digifico, Elisabeth, et al.
Publicado: (2020)

A Systems Biology Approach to Characterize the Regulatory Networks Leading to Trabectedin Resistance in an In Vitro Model of Myxoid Liposarcoma
por: Uboldi, Sarah, et al.
Publicado: (2012)

Mitozolomide activity on human cancer cells in vitro.
por: Erba, E., et al.
Publicado: (1986)

Tumor treating fields affect mesothelioma cell proliferation by exerting histotype-dependent cell cycle checkpoint activations and transcriptional modulations
por: Mannarino, Laura, et al.
Publicado: (2022)

Quantitative determination of niraparib and olaparib tumor distribution by mass spectrometry imaging
por: Morosi, Lavinia, et al.
Publicado: (2020)

Photoreceptor cKO of OTX2 Enhances OTX2 Intercellular Transfer in the Retina and Causes Photophobia
por: Pensieri, Pasquale, et al.
Publicado: (2021)

Flow cytometric analysis of DNA content in human ovarian cancers.
por: Erba, E., et al.
Publicado: (1989)

Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib
por: Caiola, Elisa, et al.
Publicado: (2018)

Homeoprotein OTX1 and OTX2 involvement in rat myenteric neuron adaptation after DNBS-induced colitis
por: Bistoletti, Michela, et al.
Publicado: (2020)

Wiring miRNAs to pathways: a topological approach to integrate miRNA and mRNA expression profiles
por: Calura, Enrica, et al.
Publicado: (2014)

Editorial: Trabectedin, lurbinectedin, and other marine-derived anticancer alkaloids on solid cancer: Mechanisms of action, clinical impact, and future perspectives
por: Zambelli, Alberto, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_60k1dnb7h0abamvtu35sepqb2t